PFE · News · 20260912N

Licensing / Collaboration Deals

PFIZER INC · 2026-09-12 · Importance 38 · Surprise 42

Pfizer is pursuing a co-development and licensing opportunity with Medicus Pharma for a CD228-targeted antibody-drug conjugate. The collaboration includes $2 million in funding for Medicus Pharma. The partnership supports Pfizer’s precision-oncology pipeline, although the reported funding is below the stated materiality threshold.